Status:

COMPLETED

Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants

Lead Sponsor:

Eli Lilly and Company

Collaborating Sponsors:

Loxo Oncology, Inc.

Conditions:

Healthy

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

The main purpose of this study is to learn about how H2 antagonist (ranitidine) and proton pump inhibitor (PPI) (omeprazole) affect Selpercatinib in healthy participants. Information about safety and ...

Eligibility Criteria

Inclusion

  • Male or female participants of non-childbearing potential who are agreeable to take birth control measures until study completion
  • Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kilograms per meter squared (kg/m²) and had a minimum weight of at least 50 kg at screening
  • Have normal blood pressure, pulse rate, electrocardiogram (ECG), and blood and urine laboratory test results that are acceptable for the study

Exclusion

  • Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
  • Have previously participated or withdrawn from this study
  • Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Had blood loss of more than 500 milliliters (mL) within the previous 30 days of study screening
  • Require treatment with inducers or inhibitors of cytochrome P450 (CYP) CYP3A within 14 days before the first dose of study drug through the end of Period 2

Key Trial Info

Start Date :

July 8 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 3 2019

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT05338502

Start Date

July 8 2019

End Date

September 3 2019

Last Update

October 30 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Covance Clinical Research Unit, Inc.

Madison, Wisconsin, United States, 53704

Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants | DecenTrialz